The risk of long-term morbidity and mortality in patients with chronic hepatitis c : Results from an analysis of data from a department of veterans affairs clinical registry

JAMA Internal Medicine

Volumn 174, Issue 2, 2014, Pages 204-212

  McCombs, Jeffrey ^a   Matsuda, Tara ^a,b   Tonnu Mihara, Ivy ^b   Saab, Sammy ^c   Hines, Patricia ^d   L'Italien, Gilbert ^d   Juday, Timothy ^d   Yuan, Yong ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BOCEPREVIR; CONSENSUS INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELAPREVIR;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DEATH; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; VIRUS LOAD;

FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MORBIDITY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SURVIVAL RATE; TIME FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84893559399     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.12505     Document Type: Article

References (36)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(suppl 1):74-81.
2. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52.
3. Armstrong GL,Wasley A, Simard EP, McQuillan GM, KuhnertWL, AlterMJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10): 705-714.
4. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090-1101.
5. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int. 2009;29(suppl 1):89-99.
6. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55(suppl 1):S3-S9.
7. Smith BD, Morgan RL, Beckett GA, et al; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
8. Butt AA,Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50(2):387-392.
9. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-3230.
10. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9(4):331-338.
11. Rein DB, Wittenborn JS,Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43(1):66-72.
12. Kallwitz ER, Layden-Almer J, Dhamija M, et al. Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol. 2010;8(1):72-78.
13. Lee MH, Yang HI, Lu SN, et al Chronic hepatitic C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469-477.
14. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-2593.
15. Backus LI, Gavrilov S, Loomis TP, et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J AmMed Inform Assoc. 2009;16(6):775-783.
16. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-36.
17. Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325.
18. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(11):923-930.
19. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012;56(2):320-325.
20. Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology. 1996;24(5):1041-1046.
21. Gordon FD, Poterucha JJ, Germer J, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation. 1997;63(10):1419-1423.
22. Larsen C, Bousquet V, Delarocque-Astagneau E, Pioche C, Roudot-Thoraval F, Desenclos JC; HCV Surveillance Steering Committee; HCV Surveillance Group. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol. 2010;82(10):1647-1654. doi:10.1002/jmv.21850.
23. Crosse K, Umeadi OG, Anania FA, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol. 2004;2(6):463-468.
24. Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol. 2004;2(6):469-473.
25. Castéra L, Hézode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004;53(3):420-424.
26. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18(10):e516-e522.
27. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20(10):669-677.
28. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013;15(1):305.
29. McHutchison JG, Everson GT, Gordon SC, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827-1838.
30. Poordad F, McCone J Jr., Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
31. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
32. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
33. Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428.
34. Fusfeld L, Aggarwal J, Dougher C, et al. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis. 2013;13(1):234-245.
35. Center for Quality Management in Public Health. The State of Care for Veterans With Chronic Hepatitis C. Palo Alto, California: US Dept of Veteran Affairs, Public Health Strategic Health Care Group, Center for Quality Management in Public Health; 2010.
36. McCombs JS, Shin J, Hines P, Yuan Y, Saab S. Impact of drug therapy adherence in patients with hepatitis C. Am J Pharmacy Benefits. 2012;4(special issue):SP19-SP27.